119 related articles for article (PubMed ID: 18720757)
21. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
22. Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias.
Laskowska J; Lewandowska-Bieniek J; Szczepanek J; Styczyński J; Tretyn A
J Gene Med; 2016 Aug; 18(8):165-79. PubMed ID: 27280600
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.
Gottardo NG; Hoffmann K; Beesley AH; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Baker DL; Kees UR
Br J Haematol; 2007 May; 137(4):319-28. PubMed ID: 17456054
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetics, natural history and the demise of childhood leukaemia.
Greaves M
Eur J Cancer; 1999 Feb; 35(2):173-85. PubMed ID: 10448256
[TBL] [Abstract][Full Text] [Related]
25. Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
Rose-James A; Shiji R; Kusumakumary P; Nair M; George SK; Sreelekha TT
Med Oncol; 2016 Sep; 33(9):98. PubMed ID: 27449773
[TBL] [Abstract][Full Text] [Related]
26. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
Tasian SK; Hunger SP
Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
[TBL] [Abstract][Full Text] [Related]
27. Stem cell origins of leukaemia and curability.
Greaves MF
Br J Cancer; 1993 Mar; 67(3):413-23. PubMed ID: 8439493
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia.
Ghodousi ES; Rahgozar S
J Cell Biochem; 2018 Jul; 119(7):6024-6032. PubMed ID: 29630744
[TBL] [Abstract][Full Text] [Related]
29. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia.
Matheson EC; Hall AG
Carcinogenesis; 2003 Jan; 24(1):31-8. PubMed ID: 12538346
[TBL] [Abstract][Full Text] [Related]
30. Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia.
Styczyński J; Wysocki M
Haematologia (Budap); 2002; 32(4):313-25. PubMed ID: 12803106
[TBL] [Abstract][Full Text] [Related]
31. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui CH
Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
33. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
[TBL] [Abstract][Full Text] [Related]
34. Childhood acute lymphoblastic leukemia in the age of genomics.
Carroll WL; Bhojwani D; Min DJ; Moskowitz N; Raetz EA
Pediatr Blood Cancer; 2006 May; 46(5):570-8. PubMed ID: 16365862
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.
Fulda S
Br J Haematol; 2009 May; 145(4):441-54. PubMed ID: 19298593
[TBL] [Abstract][Full Text] [Related]
36. Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
Bhojwani D; Moskowitz N; Raetz EA; Carroll WL
Paediatr Drugs; 2007; 9(3):149-56. PubMed ID: 17523695
[TBL] [Abstract][Full Text] [Related]
37. ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia.
Abdullah M; Choo CW; Alias H; Abdul Rahman EJ; Mohd Ibrahim H; Jamal R; Hussin NH
Hematology; 2017 Aug; 22(7):386-391. PubMed ID: 28292214
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F
Biochem Pharmacol; 2009 Apr; 77(8):1410-7. PubMed ID: 19426680
[TBL] [Abstract][Full Text] [Related]
39. Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids.
Lönnerholm G; Nordgren A; Frost BM; Jonsson OG; Kanerva J; Nygaard R; Schmiegelow K; Larsson R; Forestier E
Leukemia; 2009 Jan; 23(1):209-12. PubMed ID: 18615108
[No Abstract] [Full Text] [Related]
40. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
Aplenc R; Lange B
Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
